Pfizer Reports P-II Study Results of GBS6 to Prevent Group B Streptococcus Infections
- The P-II study results evaluate the safety & immunogenicity of Group B Streptococcus (GBS) maternal vaccine candidate GBS6 in healthy nonpregnant women and pregnant women aged 18-40yrs. and their infants
- The P-II study results from pregnant individuals showed that GBS6 was generally well-tolerated and generated robust maternal Ab responses against the six GBS CPS serotypes & these Abs were efficiently transferred to infants. The safety profile was similar b/w vaccine and PBO groups in both the mothers and infants with similar solicited systemic events
- In pregnant individuals & infants, AEs were reported in 45-70% vs 61% & 62-75% vs 74%, respectively. The results were published in the NEJM
Ref: Pfizer | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.